[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336956-105":59,"doc-detail-336956-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","assessment-of-cancer-risk-associated-with-7-nitroso-3-trifluoromethyl-5678-tetrahydro-124-triazolo-43-apyrazine-contaminated-sitagliptin-use-a-retrospective-cohort-study","Assessment of cancer risk associated with 7-nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro [1,2,4] triazolo-[4,3-a]pyrazine-contaminated sitagliptin use - A retrospective cohort study","","The study evaluates whether sitagliptin contaminated with NTTP impurities is associated with a higher cancer risk than other DPP-4 inhibitors. A Japanese retrospective cohort used national insurance claims and specific health checkups covering more than 120 million people, comparing sitagliptin users with other DPP-4 inhibitor users over 3 years of exclusive use. Results showed no meaningful increase in overall cancer incidence or in hazard ratios, with consistent findings across cancer types and sensitivity analyses.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/assessment-of-cancer-risk-associated-with-7-nitroso-3-trifluoromethyl-5678-tetrahydro-124-triazolo-43-apyrazine-contaminated-sitagliptin-use-a-retrospective-cohort-study/336956/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/assessment-of-cancer-risk-associated-with-7-nitroso-3-trifluoromethyl-5678-tetrahydro-124-triazolo-43-apyrazine-contaminated-sitagliptin-use-a-retrospective-cohort-study/336956.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What prompted this research on sitagliptin and cancer risk?","Question",{"text":112,"@type":113},"A US FDA report raised concerns about nitrosamine impurities (NTTP) in sitagliptin and their potential carcinogenicity, prompting safety investigations including cancer risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study designed and what data were used?",{"text":117,"@type":113},"It was a retrospective cohort study using Japan’s National Database of Health Insurance Claims and Specific Health Checkups, covering data from April 2012 to March 2021 and analyzing patients who initiated DPP-4 inhibitor therapy.",{"name":119,"@type":110,"acceptedAnswer":120},"Did sitagliptin contaminated with NTTP increase overall cancer incidence?",{"text":121,"@type":113},"No. The incidence rate ratio was 0.99 with a 95% confidence interval of 0.97–1.02, and a Cox model showed no significant association (hazard ratio 1.01, 95% confidence interval 0.98–1.04).",{"name":123,"@type":110,"acceptedAnswer":124},"Were results consistent for different cancer types and robustness checks?",{"text":125,"@type":113},"Yes. Findings were consistent across cancer types and across sensitivity analyses, including analyses with different exposure periods.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},336956,1790198586,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","ORIGINAL ARTICLE  \nAssessment of cancer risk associated with 7-nitroso-3-(triﬂuoromethyl)-5,6,7,8-tetrahydro [1,2,4] triazolo-[4,3-a]pyrazine-contaminated sitagliptin use: A retrospective cohort study  \nTakehiro Sugiyama1,2,3,4*, Takashi Furuno2, Yuichi Ichinose5,6, Masao Iwagami3,4, Noriko Ihana-Sugiyama1,7, Kenjiro Imai1, Tamaki Kakuwa5,6, Ryoko Rikitake5,6, Mitsuru Ohsugi1,7, Takahiro Higashi5,6, Hiroyasu Iso2, Kohjiro Ueki7,8  \n1Diabetes and Metabolism Information Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan, 2Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan, 3Department of Health Services Research, Institute of Medicine, University of Tsukuba, Ibaraki, Japan, 4Health Services Research and Development Center, University of Tsukuba, Ibaraki, Japan, 5Division of Health Services Research, National Cancer Center, Tokyo, Japan, 6Department of Public Health/Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 7Department of Diabetes, Endocrinology, and Metabolism, National Center for Global Health and Medicine, Tokyo, Japan, and 8Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan  \nKeywords  \nNitrosamines, Pharmacoepidemiology, Sitagliptin phosphate  \n*Correspondence Takehiro Sugiyama Tel.: +81-3-3202-7181  \nFax: +81-3-3207-1038  \nE-mail address:  \n[tsugiyama@hosp.ncgm.go.jp](tsugiyama@hosp.ncgm.go.jp)  \n[J Diabetes Investig](J Diabetes Investig 2024)[ 2024](J Diabetes Investig 2024); [15: 1556](15: 1556)– 1565  \ndoi: 10.1111/jdi.14281  \nABSTRACT  \nAims/Introduction: A recent US Food and Drug Administration report highlighted concerns over nitrosamine (7-nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4] triazolo-[4,3-a]pyrazine [NTTP]) impurities in sitagliptin, prompting investigations into its safety profile. The present study aimed to determine if the use of NTTP-contaminated sitagliptin, in comparison with other dipeptidyl peptidase-4 (DPP-4) inhibitors, is associated with an increased cancer risk.  \nMaterials and Methods: This retrospective cohort study secondarily used the National Database of Health Insurance Claims and Specific Health Checkups of Japan, encompassing data on > 120 million individuals. The study involved patients who initiated DPP-4 inhibitor therapy (sitagliptin or other DPP-4 inhibitors) and continued its exclusive use for 3 years. Sitagliptin users were compared with other DPP-4 inhibitor users for assessing the occurrence of cancers, as defined by diagnosis codes. Further analyses focused on specific types of cancer, using either diagnosis codes or a combination of diagnosis and procedure codes. We also carried out various sensitivity analyses, including those with different exposure periods.  \nResults: Sitagliptin users (149,120 patients, 388,356 person-years) experienced 9,643 cancer incidences (2,483.0/100,000 person-years) versus 12,621 incidences (2,504.4/100,000 person-years) among other DPP-4 inhibitor users (199,860 patients, 503,952 person-years), yielding a minimal difference (incidence rate ratio 0.99, 95% confidence interval 0.97–1.02). A multiple Cox proportional hazards model showed no significant association between sitagliptin use and overall cancer incidence (hazard ratio 1.01, 95% confidence interval 0.98–1.04). Findings were also consistent across cancer types and sensitivity analyses. Conclusions: We observed no evidence to suggest an increased cancer risk among patients prescribed NTTP-contaminated sitagliptin, although continued investigation is needed.  \nReceived 31 May 2024; accepted 19 July 2024  \n1556 J Diabetes Investig Vol. 15 No. 11 November 2024 ª 2024 The Author(s). Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the te","cbCaifqZ11PkP5pW","https://ap.wps.com/l/cbCaifqZ11PkP5pW","pdf",675909,"English","# Abstract\n## Aims/Introduction\n## Materials and Methods\n## Results\n## Conclusions\n# Introduction\n## Regulatory background and rationale\n# Materials and Methods\n## Design, setting and participants\n## Outcomes and analyses","[{\"question\":\"What prompted this research on sitagliptin and cancer risk?\",\"answer\":\"A US FDA report raised concerns about nitrosamine impurities (NTTP) in sitagliptin and their potential carcinogenicity, prompting safety investigations including cancer risk.\"},{\"question\":\"How was the study designed and what data were used?\",\"answer\":\"It was a retrospective cohort study using Japan’s National Database of Health Insurance Claims and Specific Health Checkups, covering data from April 2012 to March 2021 and analyzing patients who initiated DPP-4 inhibitor therapy.\"},{\"question\":\"Did sitagliptin contaminated with NTTP increase overall cancer incidence?\",\"answer\":\"No. The incidence rate ratio was 0.99 with a 95% confidence interval of 0.97–1.02, and a Cox model showed no significant association (hazard ratio 1.01, 95% confidence interval 0.98–1.04).\"},{\"question\":\"Were results consistent for different cancer types and robustness checks?\",\"answer\":\"Yes. Findings were consistent across cancer types and across sensitivity analyses, including analyses with different exposure periods.\"}]","Assessment of cancer risk associated with 7-nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro [1,2,4] triazolo-[4,3-a]pyrazine-contaminated sitagliptin use - A retrospective cohort study | PDF",1790017193,25,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b6fd96197cfe055ee5c596846c92899.webp",983,1291,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d24b4309b584b5b2b2525eab0ed32779.webp",982,1290,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecd1d362c5acfa37a9156cea539bedf3.webp",981,1289,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3bfe5c737bce9fab8258c525de1c37fc.webp",980,1287]